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A B S T R A C T
This study investigated whether the prevalence of
human papilloma virus (HPV) in association with
Chlamydia trachomatis, herpes simplex virus
(HSV)-1 and ⁄ or HSV-2 was greater in high-grade
than in low-grade or control cervical biopsy
specimens. HPV-positive (n = 86) and HPV-neg-
ative (n = 213) women were screened for HPV,
HSV and C. trachomatis by PCR. The most com-
mon HPV genotypes were HPV-16, HPV-6 and
HPV-33; mixed HPV infection (n = 12) was also
seen. A higher prevalence of C. trachomatis, HSV-1
and HSV-2 was found in HPV-positive samples.
High-risk HPV genotypes and combined
HPV + C. trachomatis or HPV + HSV-1, but not
HSV-2, infections were associated with a greater
risk of developing cervical carcinoma.
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Human papilloma virus (HPV) is the main aetio-
logical factor in cervical neoplasia [1]. However,
the high incidence and long latency of HPV
suggest that additional factors are involved in
inducing cervical intra-epithelial neoplasia (CIN)
[1,2], including herpes simplex virus (HSV) [3]
and Chlamydia trachomatis [4,5]. These factors act
by increasing the HPV-associated CIN risk
through several mechanisms, including modula-
tion of host immunity. Previous infection has
been reported to be the most significant factor for
HPV persistence [5], and a relationship between
HPV and other sexually transmitted infections
has been suggested. The presence of HSV-2 in
HPV-positive cases suggests that it could initiate
mutations and carcinogenesis [6,7], and may act
with HPV in increasing the risk of CIN [7,8],
although contradictory results have also been
obtained [9]. C. trachomatis has also been associ-
ated with an increased risk of cervical neoplasia
in HPV-positive patients [8], with the risk im-
parted by C. trachomatis being proportional to its
titre, which is elevated in older women [4]. The
present study investigated the association be-
tween HPV and HSV-1, HSV-2 and ⁄ or C. tracho-
matis, and correlated the results with other CIN
risk-factors.
In total, 299 women (86 HPV-positive and 213
HPV-negative, based on Pap smear tests and
confirmed by PCR [10]) attending obstetrics and
gynaecology outpatient clinics were recruited to
the study (Table 1), and were asked to complete
and sign a standard questionnaire ⁄ consent form
after the purpose of the study was explained and
after all institutional ethical requirements were
met. Endocervical scrapings were collected using
a speculum-assisted Ayre’s spatula. Where endo-
cervical sampling could not be performed, vagi-
nal specimens (n = 14) were collected using a
sterile Ayre’s spatula after separation of the labia
minora and intra-vaginal 180 rotation of the
spatula.
HPV was amplified with the L1 consensus
primers MY09 and MY11 [10]. HPV genotypes
(HPV-6 ⁄ 11 ⁄ 16 ⁄ 18 ⁄ 33) were determined by
hybridisation with genotype-specific biotinylated
DNA probes, followed by visualisation with a
DNA enzyme immunoassay (DiaSorin, Salluggia,
Italy). C. trachomatis DNA was detected using the
Amplicor STD Amplification and CT Detection
systems (Roche Diagnostics, Mannheim, Ger-
many), with detection by hybridisation with
C. trachomatis-specific biotinylated probes. HSV-1
and HSV-2 were detected by nested PCR [11].
Statistical analysis was performed using SPSS v.13
software (SPSS Inc., Chicago, IL, USA), with
Pearson’s chi-square test used to assess inter-
group significance, and Student’s t-test used to
determine differences in means.
While HPV-positive women were comparable
to HPV-negative women in terms of age and
previous pregnancies, a higher prevalence of
smokers, women with multiple male sexual part-
ners and women with positive Pap smears was
seen among HPV-positive women (Table 1). Of
the 64 HPV-positive women with abnormal cytol-
ogy, 42 were graded CIN I, six were graded
CIN II, and 16 were graded CIN III; all abnormal
cytology results in HPV-negative women were
graded CIN I (Table 1). The most prevalent gen-
otypes were HPV-16 (n = 48), HPV-6 (n = 10) and
HPV-33 (n = 6). Mixed HPV infections (n = 12)
included eight patients with high-risk ⁄high-risk
(HR ⁄HR) genotypes and four with high-risk ⁄
low-risk (HR ⁄LR) genotypes. The mean age of
C. trachomatis-positive (n = 29), HSV-1-positive
(n = 40) and HSV-2-positive (n = 33) women
was comparable to that of HPV-positive cases.
Abnormal cytology was significantly greater in
women with HPV-16 and mixed HR ⁄HR infec-
tions, as well as in those with HSV-1 and
C. trachomatis infections.
HSV-1, HSV-2 and C. trachomatis were more
prevalent among HPV-positive women (Table 2).
Combined HSV-1 ⁄HSV-2 and HSV-1 ⁄C. trachoma-
Table 1. Characteristics of study participants
Variable HPV-positive HPV-negative p OR 95% CI
Number 86 213
Age (years)
Mean ± SD 33.6 ± 7.1 33.6 ± 7.4 0.961
Range 20–50 20–59
Smokers 36 (41.9%) 54 (25.4%) 0.002 2.36 1.38–4.03
Pregnancies 65 (75.6%) 151 (70.9%) 0.477 1.27 0.72–2.26
No. partnersa
1 35 (49.3%) 137 (80.1%)
2–5 29 (40.8%) 17 (9.9%) 0.031 2.30 1.13–4.64
> 5 7 (9.9%) 17 (9.9%) 0.424 1.61 0.62–4.19
Pap smear
Negative 22 (25.6%) 192 (90.1%) < 0.001 26.60 13.73–51.54
Positive 64 (74.4%) 21 (9.9%)
CIN grade
0 22 (25.6%) 192 (90.1%)
1 42 (48.8%) 21 (9.9%) < 0.001 17.46 8.80–34.62
2 6 (7.0%) 0 < 0.001 0.103 0.07–0.15
3 16 (18.6%) 0 < 0.001 0.103 0.07–0.15
CIN, cervical intra-epithelial neoplasia; HPV, human papilloma virus.
aBased on 71 HPV-positive and 171 HPV-negative women for whom reliable
information was collected.
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tis, but not HSV-2 ⁄C. trachomatis infection, was
significantly more prevalent among HPV-positive
cases (Table 2). Predictors of abnormal cytology
were determined by logistic regression analysis,
with the dependent variable being a Pap smear
and the independent variables being age, number
of sexual partners, abortions, smoking, other
infections and HPV, C. trachomatis, HSV-1 and
HSV-2 infections. The only variables that were
selected were HPV (p < 0.001; OR 22.340) and
C. trachomatis (p 0.006; OR 5.910); HSV-1 or HSV-
2 were not associated significantly with abnormal
cytology.
It has been suggested by some studies [3,5,6],
but not by others [9], that C. trachomatis and ⁄ or
HSV are predisposing factors for HPV infection.
The present study demonstrated an increased
prevalence of C. trachomatis and HSV-1 among
HPV-positive patients, as was expected because
of the similarity in their mode of transmission
[5,12]. HPV infection was more common among
women with multiple sexual partners, and those
who were smokers or had abnormal cytology [1].
Abnormal cytology was associated with a lower
risk for CIN in HPV-negative women, as all the
abnormal cytology seen in HPV-negative women
was graded CIN 1, compared with 65.6% of
HPV-positive women who were graded CIN 1
and 34.3% who were graded CIN 2 ⁄ 3. As dem-
onstrated previously [13], including in Lebanon
[14], HPV-16 was the most prevalent genotype
among HPV-positive women with abnormal
cytology.
The association of HSV-2 with abnormal cytol-
ogy was modest compared with that of HPV [15].
While HSV-2 may cooperate with HPV, its effects
appear to be indirect, indicating that HSV-2 is not
a significant risk-factor for cervical carcinoma
[6,9], in contrast with the association between
HSV-1 and CIN in HPV-positive women [16].
Abnormal cytology was more prominent in
women with HPV-16 and mixed HR ⁄HR HPV,
C. trachomatis and HSV-1 infection. While HSV-1
and HSV-2 are associated commonly with labial
and genital lesions [17], concomitant HSV-1 infec-
tion may exert a protective role in HSV-2-infected
individuals [18]. In contrast, it has also been
suggested that HSV-2 induces CIN, which be-
comes more pronounced with HPV infection [16].
HPV-positive women harbouring HSV-1, or
both HSV-1 and HSV-2, were more likely to
have a positive Pap smear than HSV-2-positive
patients, suggesting that HSV-2 acts by cross-
immunising against HSV-1 [19], and ⁄ or by
inhibiting HPV expression. Abnormal cytology
was also significantly higher in patients infected
with HR ⁄HR than in those infected with HR ⁄LR
genotypes, suggesting that the timing of these
infections was crucial in precipitating abnormal
cytology, and that infection with an LR geno-
type may facilitate development of cell-medi-
ated immunity. C. trachomatis was a risk-factor
for HPV persistence [5], and may act as a co-
factor with HPV in precipitating abnormal
cytology by inducing expression of pro-inflam-
matory mediators [20], altering cell-to-cell adhe-
sion, and affecting cellular differentiation [20].
The results of the present study are in agree-
ment with studies that linked C. trachomatis with
cervical neoplasia after controlling for HPV, but
contradict others that found no association
between C. trachomatis and low-grade CIN in
HPV-adjusted analyses. Accurate determination
of HPV and other co-infections in relation to
cervical cancer is of relevance in assessing the
role of these sexually transmitted infections in
cervical diseases.
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The best antibiotic regimen for acute prosthetic
joint infection, treated without removal of the
implant, has not been well-defined. This study
describes the use of a protocol based on oral
rifampicin combinations to treat 47 cases that
were followed prospectively for a 2-year period.
The regimen used most commonly was levofloxa-
cin 500 mg ⁄ 24 h plus rifampicin 600 mg ⁄ 24 h for
a mean duration of 2.7 ± 1 months. The cure rate
was 76.9%, and the only independent risk-factor
associated with treatment failure was infection
caused by methicillin-resistant Staphylococcus au-
reus or Enterococcus spp. (OR 17.6, p 0.003).
Overall, the results suggested that use of oral
antibiotics, including rifampicin, for 2–3 months
was a good treatment option.
Keywords Acute prosthetic joint infection, antibiotic
regimen, levofloxacin, rifampicin, treatment
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Acute post-surgical prosthetic infection can be
treated successfully by open debride´ment and
prolonged intravenous antimicrobial therapy.
However, it has not yet been established which
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